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Abstract
Background
Type 2 diabetes (T2D) has a reported greater prevalence and poorer treatment outcomes in
people living with HIV (PLWH) than comparable HIV-uninfected cohorts. We conducted a
cross-sectional study to delineate the factors driving T2D in PLWH in an ethnically diverse
cohort, and additionally observed how these have changed over time.
Setting
We studied a diverse HIV cohort in London to determine the prevalence and risk factors for
T2D, and compared them to a cohort studied 10 years previously.
Methods
Patients were classified as normoglycaemic (fasting glucose <6.0 mmol/l) or dysglycaemic
(6.0 mmol/l). The relative contribution to dysglycaemia of modifiable and fixed factors,
including demographics, anthropometrics, comorbidities, immune status, and HIV therapy,
were analysed using univariate and logistic regression analyses.
Results
T2D prevalence was 15.1% in 2015 with a relative risk of 2.4 compared to the general popu-
lation. The prevalence compared to 6.8% ten years earlier. The 2015 versus the 2005 cohort
was significantly older (median age 49 (42–57) years versus 41 (IQR 35–47), p<0.001), had
a higher BMI (27.4 (23.3–29.9) versus 24.9 (22.4–28.0) kg/m2 respectively, p = 0.019) and
hypertensive (37.9% versus 19.6 respectively, p<0.001). The strongest predictors of dysgly-
caemia in the 2015 cohort were hepatic steatosis and hypertension, odds ratios (OR) and
95% confidence intervals (CI) 6.74 (3.48–13.03) and 2.92 (1.66–5.16) respectively, and
also HIV-related factors of weight gain following antiretroviral initiation and longer known
duration of HIV infection (OR 1.07 (1.04–1.11) and 1.06 (1.02–1.10) respectively).
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Conclusions
The alarmingly high prevalence of T2D in HIV requires improved screening, targeted to
older patients and those with a longer duration of exposure to antiretrovirals. Effective diabe-
tes prevention and management strategies are needed urgently to reduce this risk; such
interventions should target both conventional risk factors, such as abdominal obesity, and
HIV-specific risk factors such as weight gain following initiation of antiretrovirals.
Introduction
Combination antiretroviral (ARV) therapy for people living with HIV (PLWH) has led to a
marked reduction in HIV-associated morbidity and mortality since its introduction in the
mid-1990s. Much of the disease burden in PLWH is now due to morbidities found in the gen-
eral population. HIV itself, and some of the ARVs used to treat it, are associated with an
increased risk and premature development of chronic comorbidities, including type 2 diabetes
(T2D), which is reported to be up to four times more prevalent in PLWH than those without
HIV [1,2].
Risk factors for T2D in the general population are well established [3] but in HIV there are
additional specific risk factors, including duration of HIV infection, degree of immunosup-
pression, and exposure to those ARVs known to be associated with dysglycaemia [4,5]. Specific
ARVs, with a variable contribution from HIV infection itself, are associated with an increased
risk of metabolic diseases, including redistribution of fat and other manifestations of lipody-
strophy, dyslipidaemia, and higher rates of comorbidities associated with ageing, including
myocardial infarction and T2D [6]. Despite improvements in ARVs, the prevalence of conven-
tional T2D risk factors appear to be increasing in HIV patients as the population ages [7]. It is
important to understand the reasons for the increase in T2D in PLWH in order to effectively
target early prevention strategies. In this cross-sectional study of an ethnically diverse cohort
we aimed to undertake a detailed exploration of risk factors contributing to prediabetes and
T2D, and to identify demographic and clinical differences over time.
Methods
We recruited HIV patients from three London outpatient clinics serving an ethnically diverse
HIV prevalent area. Data were collected at two time periods, 2005 and 2014/15. The 2005
cohort was studied as part of a substantive investigation of the metabolic profile of HIV [8].
The 2014–2015 cohort participants were recruited to enable an in-depth examination of fac-
tors associated with risk of type 2 diabetes, and secondarily to facilitate a comparison over
time. Research Ethics Committee approval was granted (UK Health Research Authority refer-
ence 13 LO 1543) and participants gave written informed consent.
For the 2005 cohort the approach to random selection of clinic attendees and data collec-
tion has been described previously [9]. In summary, every third patient attending outpatients
was invited to participate, with recruitment from specialist metabolic clinics excluded. Patients
attending these specialist clinics could be recruited from general attendance. For the present
analyses, the subset of participants for whom fasting blood glucose data were available were
included (n = 337), 33.0% of the total cohort. Sensitivity analyses were conducted to compare
the subset of participants with the full cohort; no significant differences were found in demo-
graphic, medical or HIV characteristics of the cohorts (S1 Table).
Type 2 diabetes in HIV
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The 2014/15 cohort was recruited using structured random sampling. A 48-cell grid strati-
fied by ten-year age bands, gender and ethnicity (White, Black African, Black Caribbean,
Other) was constructed to exactly mirror the demographic spread for those parameters of all
HIV patients attending the clinics. We aimed to ensure the diversity of the cohort was repre-
sented as women and minority ethnic groups are routinely underrepresented in clinical
research [10]. Recruitment was halted to each cell on achievement of individual targets. Partic-
ipants were recruited through a combination of self-referral in response to within-clinic adver-
tising, sampling of every third clinic attendee, and by healthcare professional referral. All
patients were eligible to participate except those unable to provide informed consent or com-
municate adequately during study procedures, or those serving custodial sentences. Sample
size was calculated using assumptions from the 2005 data indicating a prevalence of dysglycae-
mia of 25% with a mean BMI of 25.8 kg/m2. With absolute and type 1 errors both set at 5% the
sample size was calculated to be 339.
In both cohorts each participant attended a research data collection visit and information
was collected from medical record review. At the assessment visit data collected prospectively
included: body mass index (BMI) measured using calibrated electronic weighing scales and
stadiometer, and categorised as underweight (<18.5 kg/m2), normal (18.5–24.9 kg/m2), over-
weight (25.0–29.9 kg/m2) and obese (30.0 kg/m2) [11]; waist measured using a non-stretch
tape and categorised as normal or centrally obese using International Diabetes Federation
(IDF) criteria [11]; hypertension determined as the mean of three blood pressure measure-
ments greater than 140/80 mm Hg (measured by electronic sphygmomanometer) or current
antihypertensive use [12]; smoking status categorised as current, never, or ex-smoker; serum
vitamin D concentration (defined as most recent within 3 years of data collection); 10-year
cardiovascular (CVD) risk calculated using the Framingham tool [13]; and dyslipidaemia
(defined as total cholesterol, LDL cholesterol or triglycerides above 5.2 mmol/l, 3.0 mmol/l
and 2.2 mmol/l respectively, or HDL cholesterol below 1.2 mmol/l, measured from fasting
phlebotomy at the visit. All participants attended after an overnight 10–12 hour fast for assess-
ment of fasting plasma glucose, and were stratified according to glycaemic status by either a
recorded diagnosis of T2D, or a confirmed fasting glucose: normal (5.9 mmol/l), impaired
fasting glucose (6.0–6.9 mmol/l), and T2D (7.0 mmol/l). Additionally at the research visit
the following variables were recorded from the medical notes and verified by the participant:
age; gender; ethnicity; history of CVD; duration of HIV infection; current and historic ARV
type and duration of treatment; current HIV suppression; lipodystrophy defined as current or
historic by participant recall and/or physician diagnosis from the medical notes; and current
hepatitis co-infection (successful clearance of Hepatitis C categorised as negative). All blood
samples were analysed in the same laboratory for consistency. Data were anonymised.
In 2015 the data collection was extended to include a broader range of risk factors including
variables assessed from the medical notes and verified by the participant at the research visit:
intake of fruits and vegetables (five daily portions is the national guideline intake [14]); weekly
hours of physical activity (exertion greater than usual walking pace); history of CVD and
stroke recorded separately; family history of diabetes; current chronic kidney disease; and his-
toric weight change in the 12 months following initiation of ARVs. Additional variables were
assessed from the medical notes including: current hepatic steatosis assessed using standard
clinical definitions by biopsy, MRI scan, or assessed by Fibroscan with an attenuation greater
than 250 [15]; and CD4 nadir.
The following ARVs were categorised as most associated with the development of insulin
resistance, according to a review of published literature: zidovudine, didanosine, stavudine,
zalcitabine, indinavir, and high-dose ritonavir [1,4,16,17]. Metabolic syndrome was defined
using IDF criteria [11]. Known duration of HIV infection and of ARV therapy were measured
Type 2 diabetes in HIV
PLOS ONE | https://doi.org/10.1371/journal.pone.0194199 March 12, 2018 3 / 11
from the dates of the first known positive HIV antibody test and first use of any ARV,
respectively.
Data analysis
Data were analysed using IBM SPSS, version 22. Continuous variables were checked for nor-
mality. All variables were categorised as fixed other than these categorised as modifiable: BMI,
waist, hypertension, dyslipidaemia, dietary intake, physical activity, and hepatic steatosis.
Characteristics of the 2005 and 2015 cohorts were compared, and differences between the two
were calculated and assessed for statistical significance using Chi-squared and ANOVA tests.
For the 2015 cohort, the relative risk of developing diabetes compared to the general popula-
tion was estimated using the QDiabetes score [18]. Patients with prediabetes (impaired fasting
glucose) and T2D were combined into a single group, ‘dysglycaemia’, and differences between
normal and dysglycaemia were analysed using Chi-squared and ANOVA tests. Significantly
co-linear variables were excluded from further analysis. Variables significantly associated with
dysglycaemia were used to construct multiple logistic regression models with backwards step-
wise removal. Modifiable and fixed factors were modelled separately, and finally all factors
were modelled together to estimate relative odds ratio (OR) contributions to predict
dysglycaemia.
Results
Cohort characteristics
The 2005 cohort consisted of 337 participants (77% male) and the 2015 cohort consisted of
338 participants (74% male) (S1 Fig). The clinical characteristics of the cohorts are shown
(Table 1). Both cohorts were ethnically diverse, with 61 countries of birth documented in 2015
reflecting the diversity of the wider London population. In 2015 58% of participants were over-
weight or obese. Compared to 2005, the 2015 cohort was older, heavier, more hypertensive,
had been HIV positive for longer, and were more likely to have been treated with ARVs, but
had lower rates of smoking and lipodystrophy. Participants in this study experienced no
adverse events. There was no missing data other than a lack of vitamin D measurement for 138
participants.
Dysglycaemia
The prevalence of dysglycaemia was 24.9% in 2005 compared to 32.3% in 2015. The prevalence
of impaired fasting glucose excluding T2D did not differ between the cohorts (2005: 18.1 vs
2015: 17.2%, p = 0.763). However, the prevalence of T2D was significantly higher in 2015 com-
pared to 2005 (2005: 6.8 vs 2015: 15.1%, p = 0.003). In the 2015 cohort, using the QDiabetes
Score the relative risk of T2D was estimated at 2.4. Factors associated with dysglycaemia are
shown in Table 2. Those significantly associated with dysglycaemia at both time points
included age and waist circumference (2005 and 2015, p<0.001), hypertension (2005
p = 0.001; 2015 p<0.001), duration of HIV infection (2005 p = 0.046; 2015 p<0.001) and the
use of ARVs (2005 p = 0.018; 2015 p = 0.009). Exposure to ARVs associated with diabetes and
BMI were both significantly correlated in 2015 only (2005 p = 0.878; 2015 p = 0.002; p = 0.423
and p = 0.001 respectively). Factors measured only in 2015 significantly associated with dysgly-
caemia were hepatic steatosis, low levels of physical activity and weight gain following initia-
tion of ARVs (p<0.001 for all).
We conducted logistic regression analysis, modelling factors associated with dysglycaemia
in our 2015 cohort. Our first model examined the predictive nature of modifiable risk factors,
Type 2 diabetes in HIV
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the second looked at fixed factors and the final model examined all factors. All three models
showed statistical significance (all p<0.001) (Table 3). Modifiable factors (hepatic steatosis,
hypertension, HDL: triglyceride ratio and physical activity) predicted dysglycaemia more
strongly than fixed and HIV-related factors (age, duration of HIV infection and weight gain
following initiation of ARVs), with hepatic steatosis (OR 7.28, p<0.001) and hypertension (OR
2.58, p = 0.003) the strongest predictors.
Discussion
In this ethnically diverse cohort of HIV patients we have shown that there is an alarmingly
high prevalence of dysglycaemia: approximately 1 in 3 patients have prediabetes or T2D. We
have determined the role of a range of both HIV-specific and conventional risk factors in pre-
dicting the prevalence of T2D, and demonstrated the importance of modifiable risk factors.
Compared to 2005 the 2015 cohort were older, had longer duration of HIV status and greater
exposure to ART therapy, all significant determinants of dysglycaemia. However, our analysis
also recognised the importance of a number of other determinants such as central adiposity
which were more prevalent in the 2015 cohort. Given the burden of T2D in PLWH there is an
Table 1. Clinical characteristics of the 2005 and 2015 cohorts.
2005
(n = 337)
2015
(n = 338)
p
GENDER Male 77.2% 74.0% 0.335a
AGE (Years) Median (IQR) 41 (35–47) 49 (42–57) <0.001b
ETHNICITY White 54.6% 49.7% 0.525a
Black African 28.2% 31.7%
Black Caribbean 5.9% 7.7%
Other 11.3% 10.9%
TYPE 2 DIABETES 6.8% 15.1% 0.003a
BMI (kg/m2) Median (IQR) 24.9 (22.4–28.0) 27.4 (23.3–29.9) 0.019b
WAIST (IDF DEFINITION) Obese 47.7% 62.4% 0.024a
(cm) Median (IQR) 91 (83–98) 95 (86–104) 0.055b
HYPERTENSION % 19.6% 37.9% <0.001a
LIPIDS (mmol/l) Total Cholesterol (SD) 4.8 ±1.0 5.0 ±1.1 0.242b
HDL: TG Ratio (SD) 1.59 ±1.74 1.39 ±1.19 0.180b
METABOLIC SYNDROME (IDF DEFINITION) % 22.5% 31.8% <0.001b
SMOKING Current 35.6% 21.0% 0.019a
CARDIOVASCULAR DISEASE (includes stroke) 2.7% 5.6% 0.055a
STATIN USE Current 16.0% 27.2% <0.001a
% 10-YEAR CVD RISK (Framingham) Mean (SD) 4.4 ±5.4 12.1 ±12.3 <0.001b
HIV Duration (Years) Mean (SD) 6.3 ±0.9 11.6 ±0.9 <0.001b
ANTIRETROVIRALS (ARVs) Naïve 19.6% 8.0% <0.001a
ARVs ASSOCIATED WITH T2D Current or historic 23.4% 44.1% <0.001a
LIPODYSTROPHY Current or historic 27.3% 21.6% 0.007a
HEPATITIS B Current 4.5% 9.2% 0.021a
HEPATITIS C Current 3.6% 4.7% 0.433a
a Difference between 2005 and 2015 by Chi-squared or Fishers-exact tests;
b Difference between 2005 and 2015 by ANOVA test.
ARVs: Antiretrovirals; BMI: Body Mass Index; CVD: Cardiovascular Disease; HDL: High Density Lipoprotein Cholesterol; IDF: International Diabetes Federation; IQR:
Interquartile Range; SD: Standard Deviation; TG: Triglycerides.
https://doi.org/10.1371/journal.pone.0194199.t001
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urgent need to mitigate these modifiable risk factors through intervention in terms of both
prevention and treatment.
The key risk factors for T2D in the general population, body mass and waist circumference,
disproportionately affect people from minority ethnic groups [19], and these risk factors are
Table 2. Risk factors associated with dysglycaemia in the 2005 and 2015 cohorts.
2005 2015
r p r p
GENDER 0.02 0.721a 0.03 0.311a
AGE Median Years 0.19 <0.001b 0.60 <0.001b
ETHNICITY White 0.07 0.325a 0.08 0.531a
Black African 0.06 0.506a 0.08 0.358a
Black Caribbean 0.10 0.108a 0.06 0.253a
BMId Median (kg/m2) 0.04 0.423b 0.17 0.001b
WAISTd Median 0.24 <0.001b 0.27 <0.001b
IDF Definition 0.30 <0.001a 0.26 <0.001a
HYPERTENSION Current 0.18 0.001a 0.39 <0.001a
LIPIDS Total Cholesterol 0.09 0.118b 0.05 0.438b
HDL 0.05 0.335b 0.13 0.016b
LDLc 0.10 0.072b
Triglyceridesd 0.11 0.038b 0.30 <0.001b
HDL:TG Ratio 0.08 0.130b 0.27 <0.001b
METABOLIC SYNDROME Current 0.58 <0.001a 0.63 <0.001a
SMOKING Current 0.01 0.716a 0.12 0.905a
CVD (excluding stroke) Current or historic 0.10 0.170a 0.11 0.050a
STATIN USE Current 0.14 0.043a 0.40 <0.001a
STROKE Current or historic 0.10 0.109a
% 10-YEAR CVD RISK Framingham, mean 0.07 0.210b 0.39 <0.001b
HIV Duration Mean Years 0.11 0.046b 0.18 <0.001b
ARV Treated 0.13 0.018a 0.17 0.009a
ARVs ASSOCIATED WITH DYSGLYCAEMIA 0.01 0.878a 0.16 0.002a
PERCENTAGE WEIGHT GAIN IN YEAR FOLLOWING INITITATION OF
ARVsc
0.34 <0.001b
LIPODYSTROPHY Current or historic 0.20 0.061a 0.15 0.007a
HEPATITIS B Current 0.01 0.873a 0.04 0.421a
HEPATITIS C Current 0.09 0.170a 0.01 0.930a
CD4 NADIRc Mean 0.01 0.082b
VITAMIN Dc Mean 0.11 0.134b
HEPATIC STEATOSISc Current 0.45 <0.001a
CHRONIC KIDNEY DISEASEc Current 0.10 0.073a
CORTICOSTEROID THERAPYc Current or historic 0.14 0.014a
1st or 2nd DEGREE RELATIVE WITH T2Dc 0.10 0.076a
PHYSICAL ACTIVITYc Hours per week 0.20 <0.001b
FRUITS & VEGETABLESc Portions per day 0.06 0.260b
Participants grouped as normal or dysglycaemia (impaired fasting glucose and type 2 diabetes)
r = correlation coefficient; p = significance.
a Significance by Pearson Chi-squared test with Phi correlation;
b Significance by Pearson Correlation;
c Data not collected in 2005;
d Non-normal distribution log-transformed
https://doi.org/10.1371/journal.pone.0194199.t002
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pronounced in this ethnically diverse cohort. Historically HIV was a disease associated with
wasting and premature death and therefore these conventional risk factors were of little rele-
vance. However, PLWH are now living longer and we have demonstrated that the rates of
overweight and abdominal obesity are increasing and are now comparable with the general
population [20]. Our regression models help explain the rise in T2D prevalence in our cohort,
with changes in the incidence of conventional risk factors combined with HIV-specific factors
contributing to T2D risk. The duration of HIV infection, ARV treatment and particularly the
use of metabolically toxic ARVs, weight gain following initiation of ARVs, and the presence of
lipodystrophy are all significantly associated with an increased risk of dysglycaemia. These
were more likely to affect the 2015 cohort than in 2005, apart from lipodystrophy for which we
observed a lower prevalence. Modifiable factors contributed significantly more to risk of dys-
glycaemia in our cohort than fixed factors, including age. In our cohort, hepatic steatosis and
hypertension were the strongest predictors of dysglycaemia. HIV-specific factors also contrib-
uted significantly, particularly weight gain following initiation of ARVs, mirroring other
recent observations [21]. It is not known if lifestyle treatment of hepatic steatosis directly
reduces risk of development of diabetes, however pharmacological treatment of hypertension
has been associated with a reduced risk for diabetes in the general population. Given our find-
ings suggesting a link between both hepatic steatosis and hypertension with diabetes risk, we
believe that further research is required in people living with HIV.
The prevalence of T2D in the 2005 cohort was 6.8% whilst in our 2015 cohort it was 15.1%,
driven in part by increasing age and BMI. Few studies elsewhere have examined change in
prevalence of T2D in PLWH, however a change in prevalence of T2D was observed in an eth-
nically diverse HIV cohort in France [22]. A rise in incidence was associated with age and obe-
sity, and historic exposure to ARVs linked with metabolic toxicities, as observed in the study
Table 3. Logistic regression analysis of factors predictive of dysglycaemia in the 2015 cohort.
Adjusted Odds Ratio (95% CI)
Model 1: Modifiable Factors
(n = 336)
Factor
p-value
Model 2: Fixed Factors
(n = 294)
Factor
p-value
Model 3: All Factors
(n = 293)
Factor
p-value
Physical Activity a (hours) 0.91
(0.82–1.00)
0.042
Hypertension b 2.92
(1.66–5.16)
<0.001 2.58
(1.37–4.88)
0.003
Hepatic Steatosis b 6.74
(3.48–13.03)
<0.001 7.28
(3.46–15.34)
<0.001
HDL: Triglyceride Ratio a (mmol/l) 1.56
(1.22–1.99)
<0.001 1.73
(1.32–2.27)
<0.001
% Weight Gain after ARVs a 1.07
(1.04–1.11)
<0.001 1.06
(1.02–1.10)
0.003
Age a (years) 1.06
(1.03–1.09)
<0.001 1.07
(1.03–1.10)
<0.001
Duration of HIV Infection a (years) 1.06
(1.02–1.10)
0.003
Collinearity was observed between the variables waist and BMI (Pearson correlation 0.851) and between HIV Duration and CD4 Nadir (Pearson correlation 0.365), and
the latter of each pair was excluded from regression modelling.
Continuous variables:
a; binary variables:
bModel Chi-square values: Model 1, 107.21 (p<0.001); model 2, 53.14 (p<0.001); model 3, 121.69 (p<0.001).
In Models 2 and 3 reduced participant numbers are due to exclusion of those who were not treated with ARVs or who had not yet received 12 month’s ARV treatment
in order to calculate percentage weight gain in that time.
https://doi.org/10.1371/journal.pone.0194199.t003
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presented here. Conversely, a study of a Danish population showed no increased risk for T2D
in HIV, however this study was confined to White participants, the cohort was relatively
young, and had lower levels of obesity [17]. Excess mortality when BMI is above normal has
been well-demonstrated in the general population [23], and is of concern in PLWH: in one US
cohort, multimorbidity associated with obesity affected 65% of HIV patients [24]. The preva-
lence of T2D in our 2015 cohort exceeded the upper end of a range in PLWH that has been
described as 2.6–14% [1]. This may in part reflect collection of our data as recently as 2015,
and might be a portent of a more general trend, especially given the ageing nature of the
cohort. Our high prevalence might also reflect socioeconomic challenges faced by a high pro-
portion of our largely inner city cohort. It is unlikely that the difference in sampling strategies
between the cohorts contributed to the high prevalence in 2015 as although Black Caribbean
and Black African participants were fairly represented in 2015, the difference to 2005 was not
statistically significant.
It is well established that dietary change, increased physical activity and weight loss all
reduce diabetes risk in the general population [25]. This approach may be especially relevant
to PLWH given the low levels of physical activity and fruit and vegetable consumption and
high prevalence of overweight and obesity that we observed [20]. Dietetic intervention in
PLWH has been shown to prevent weight gain and subsequent development of hyperlipidae-
mia after initiation of ARVs [26]. The association between dysglycaemia and weight gain fol-
lowing initiation of ARVs that we observed is another rationale for recommending dietetic
intervention at this stage.
The strengths and limitations of our research warrant consideration. A principle strength
for investigation of factors associated with diabetes risk in the 2015 cohort is the lack of miss-
ing data other than Vitamin D measurements. Our participants were recruited from the same
clinical cohort at two time points, and this allowed us to compare factors associated with dia-
betes risk. Clinical definitions and diagnostic criteria were applied consistently in both 2005
and 2015. At both time points glycaemic status was characterised by glucose measured in a
truly fasting state, and did not rely on HbA1c, which can be underestimated in people treated
with ARVs [27].
A limitation is that our sampling methods differed between the two cohorts, although both
included partial randomisation and excluded recruitment from specialist metabolic HIV clin-
ics. It is possible that the 2015 sample does not fairly represent the total clinical cohort consid-
ering factors other than age, gender and ethnicity, for example socioeconomic status or
educational attainment. Fewer predictor variables were collected in 2005 compared to 2015.
Data collection from 2005 was not designed to allow subgroup analysis of factors contributing
to diabetes risk, and so changes over time cannot be assessed. Regarding potential non-ARV
pharmacological contribution to dysglycaemia, data collection was limited to exposure to cor-
ticosteroids and metformin. Furthermore, medical records predating 1996 were rarely avail-
able, and we relied on participant recollection which may not have been wholly accurate.
Smoking status, physical activity levels and consumption of fruits and vegetables were self-
reported and open to misreporting. Hepatic steatosis rates derived from the medical notes
may have been overestimated in those with dysglycaemia due to selective screening in those
perceived to be at risk of hepatic fibrosis. A limitation is the lack of an HIV negative control
group for comparison.
In conclusion, the alarmingly high prevalence of T2D in our cohort of PLWH has implica-
tions for the tens of millions of PLWH worldwide. This is compounded by an increase in asso-
ciated comorbidities in PLWH, including cardiovascular disease [6]. Additionally there are
distinct challenges associated with the management of T2D in HIV. Some ARVs can impair
glycosylated haemoglobin (HbA1c) assays resulting in underestimation [27,28] and some
Type 2 diabetes in HIV
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ARVs significantly interact with hypoglycaemic agents [29]. Overall it is known that HIV
patients with T2D have a poorer response to diabetes treatments compared to matched HIV
negative individuals [30]. We suggest a response is urgently needed. Enhanced screening for
diabetes risk in PLWH should be considered and should account for the broad range of risk
factors that affect PLWH, both conventional and HIV-specific. Interventions that tackle these
risk factors are needed. Selection of ARVs with less effect on insulin resistance in those with
dysglycaemia or significant risk factors, and proactive lifestyle management of the increased
risk of diabetes that occurs due to weight gain following initiation of HAART, should be con-
sidered. Furthermore, there is an urgent need to understand whether diet and lifestyle inter-
ventions that are effective at tackling diabetes risk factors in the general population, for
example those that reduce blood pressure and hepatic steatosis, are effective in PLWH. Diabe-
tes risk should not be considered in isolation in PLWH, and disease specific screening and
management of other comorbidities in PLWH with diabetes should be undertaken [1,31].
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